

# China Insulin Industry Report, 2012-2015

<https://marketpublishers.com/r/CCE9664746CEN.html>

Date: January 2013

Pages: 70

Price: US\$ 1,800.00 (Single User License)

ID: CCE9664746CEN

## Abstracts

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.

Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so.

Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China's insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011.

America-based Eli Lilly and Company is the second embarking on Chinese insulin market, with the recombinant human insulin market share of 17% and the insulin analog market share of 8% in 2011. Moreover, Eli Lilly and Company is making constant efforts to extend business in the Chinese market. In May, 2012, Eli Lilly and Company China R&D center was formally opened in Shanghai, dedicated to the R&D of diabetes medicines; in June, the Suzhou-based insulin extension project with the investment exceeding USD40 million was also put into service.?

Jilin-based Tonghua Dongbao Pharmaceutical is China's largest recombinant human insulin producer, with the insulin API capacity of 3,000 kg and the insulin preparation capacity of 70 million bottles or 6% market share in China's recombinant human insulin market. In 2012, the company's recombinant human insulin injection phase project with the annual capacity of insulin preparation targeting 126 million pcs started construction, and it is expected to be put into production in Q4 2013.?

As the world's fourth and China's first insulin analog producer, Gan & Lee Pharmaceuticals realized the market share of 6% in China's insulin analog market in 2011. In April 2012, the insulin phase ? project of the company held the groundbreaking ceremony. Once the project is put into production as scheduled, the company is expected to increase its capacity of insulin API by 750kg/a and of insulin preparation by 38.5 mln pcs/a.

Enterprises including Hisun Pharmaceutical, United Laboratories and Bayer, with positive outlook of demand for insulin in the Chinese market, are beefing up gaining ground in China through developing new products, building new production bases and agent marketing.

The report highlights the followings:

Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc.

China insulin industry: development, supply & demand, import & export, competition pattern, policy environment, development trend, etc.

Operation, insulin business analysis and development outlook of seven insulin producers worldwide.

## Contents

### **1. INSULIN OVERVIEW**

- 1.1 Definition
- 1.2 Classification
- 1.3 Industry Chain

### **2. GLOBAL INSULIN MARKET DEVELOPMENT**

- 2.1 Status Quo
- 2.2 Supply and Demand
- 2.3 Product R&D
- 2.4 Competition Pattern
- 2.5 Development Trend

### **3. CHINA INSULIN MARKET DEVELOPMENT**

- 3.1 Status Quo
- 3.2 Supply and Demand
- 3.3 Export
- 3.4 Import
- 3.5 Competition Pattern
- 3.6 Price
- 3.7 Policy
- 3.8 Development Trend

### **4. KEY INSULIN MANUFACTURERS**

- 4.1 Novo Nordisk
  - 4.1.1 Profile
  - 4.1.2 Operation
  - 4.1.3 Revenue Structure
  - 4.1.4 Gross Margin
  - 4.1.5 R&D and Investment
  - 4.1.6 Insulin Business
  - 4.1.7 Business in China
  - 4.1.8 Development Prospect
- 4.2 Eli Lilly and Company

- 4.2.1 Profile
- 4.2.2 Operation
- 4.2.3 Revenue Structure
- 4.2.4 Gross Margin
- 4.2.5 R&D and Investment
- 4.2.6 Insulin Business
- 4.2.7 Business in China
- 4.2.8 Development Prospect
- 4.3 Sanofi Group
  - 4.3.1 Profile
  - 4.3.2 Operation
  - 4.3.3 Revenue Structure
  - 4.3.4 Gross Margin
  - 4.3.5 R&D and Investment
  - 4.3.6 Insulin Business
  - 4.3.7 Business in China
  - 4.3.8 Development Prospect
- 4.4 Tonghua Dongbao Pharmaceutical Co., Ltd.
  - 4.4.1 Profile
  - 4.4.2 Operation
  - 4.4.3 Revenue Structure
  - 4.4.4 Gross Margin
  - 4.4.5 Customers
  - 4.4.6 R & D and Investment
  - 4.4.7 Insulin Business
  - 4.4.8 Development Prospect
- 4.5 Wanbang Biopharmaceuticals
  - 4.5.1 Profile
  - 4.5.2 Operation
- 4.6 Gan & Lee Pharmaceuticals
  - 4.6.1 Profile
  - 4.6.2 Operation
- 4.7 Nanjing Xinbai Pharmaceutical Co. Ltd.
  - 4.7.1 Profile
  - 4.7.2 Operation
  - 4.7.3 Insulin Business

## Selected Charts

### SELECTED CHARTS

Diabetes Types

Classification of Insulin by Technological Level/Time

Recombinant Human Insulin Production Carrier and Features

Insulin Industry Chain

World's Population of Diabetics, 2005-2012

Population of Diabetics in the World's Top 10 Countries by Diabetes Developers, 2011

Market Size of the World's Top 10 Diabetes Medicines, 2011

Market Scale of Diabetes Medicines Worldwide and YoY Growth Rate, 2004-2011

Global Diabetics Market Occupancy by Medicine, 2006-2011

Global Insulin Market Scale and YoY Growth Rate, 2005-2011

Theoretic Demand for Insulin API Worldwide, 2011

Average Per Capita Insulin Consumption Worldwide by Nation, 2000-2010

R&D Advance of Some Insulin Products Worldwide as of late Jun. 2012

Global Insulin Pump Market Scale, 2009/2016

Global Insulin Market Share by Enterprise, 2011

Global Insulin Production Line and R&D Input Share by Enterprise, 2011

Population of Diabetics in China, 2007-2011

Market Scale of Diabetes Medicines in China and YoY Growth Rate, 2004-2011

Insulin Medicine Market Share in China, 2006-2011

Market Share of Diabetes Treatment Hospitals in China by Medicine, 2005-2010

Export Value and Export Price of Insulin and Insulin Salts of China, 2008-2012

Export Destinations of Insulin and Insulin Salts in China and Proportions, 2011

Export Value of Insulin-Containing Medicines with Unmeasured Dose in China, 2010-2012

Export Value of Insulin-Containing Medicines with Measured Dose in China by Nation and Proportions, 2011

Export Value of Insulin-Containing Medicines with Measured Dose in China and YoY Growth Rate, 2008-2012

Export Value of Insulin-Containing Medicines with Measured Dose in China by Nation, 2011

Import Value of Insulin and Insulin Salts and YoY Growth Rate in China, 2008-2011

Import Value of Insulin and Insulin Salts in China by Country, 2011

Import Value of Insulin-Containing Medicines with Measured Dose and YoY Growth Rate in China, 2008-2012

Import Value of Insulin-Containing Medicines with Measured Dose in China by Country,

2011

Import Value of Insulin Medicines in Representative Hospitals in 22 Cities across China by Variety, 2008-2011

Competitive Enterprises and Market Share in China Insulin Market, 2011

Competition Pattern of China Recombinant Human Insulin Market, 2011

Competition Pattern of China Insulin Analog Market by Enterprise, 2011

Ceiling Retail Price of Some Insulin Products in China, 2011

Insulin Medicines Included in National Health Insurance Directory, 2012

Key Strategy of Novo Nordisk

Revenue and YoY Growth Rate of Novo Nordisk, 2007-2012

Net Income and YoY Growth Rate of Novo Nordisk, 2007-2012

Revenue of Novo Nordisk by Product, 2007-2012

Revenue of Novo Nordisk by Region, 2007-2012

Gross Margin of Novo Nordisk, 2007-2012

R&D Expenditure of Novo Nordisk by Field, 2007-2011

Insulin Market Share of Novo Nordisk by Country, 2011-2012

Revenue from Insulin Business of Novo Nordisk by Mark, 2009-2012

Distribution of Subsidiaries under Novo Nordisk in China

Revenue and YoY Growth Rate of Novo Nordisk in China, 2007-2012

Revenue, Net Income and YoY Growth Rate of Novo Nordisk, 2010-2015

Revenue and YoY Growth Rate of Eli Lilly and Company, 2007-2012

Net Income and YoY Growth Rate of Eli Lilly and Company, 2007-2012

Revenue of Eli Lilly and Company by Field, 2009-2011

Revenue of Eli Lilly and Company by Region, 2009-2011

Consolidated Gross Margin of Eli Lilly and Company, 2008-2012

R&D Expenditure and YoY Growth Rate of Eli Lilly and Company, 2007-2012

Cooperative Enterprises with Eli Lilly and Company by Product, 2011

Revenue and YoY Growth Rate from Insulin Business of Eli Lilly and Company by Product, 2008-2012

Revenue from Insulin Business of Eli Lilly and Company by Region, 2008-2012

Revenue, Net Income and YoY Growth Rate of Eli Lilly and Company, 2010-2015

Revenue and YoY Growth Rate of Sanofi Group, 2007-2012

Net Income and YoY Growth Rate of Sanofi Group, 2007-2012

Revenue of Sanofi Group by Business, 2008-2012

Revenue of Sanofi Group by Region, 2008-2012

Consolidated Gross Margin of Sanofi Group, 2007-2012

R&D Expenditure of Sanofi Group by Business, 2008-2012

Revenue and YoY Growth Rate from Insulin Business of Sanofi Group by Product, 2008-2012

Distribution of Subsidiaries under Sanofi Group, 2011  
Revenue and YoY Growth Rate of Sanofi Group in China, 2009-2012  
Revenue, Net Income and YoY Growth Rate of Sanofi Group, 2010-2015  
Distribution of Subsidiaries under Tonghua Dongbao Pharmaceutical, 2011  
Revenue and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012  
Net Income and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012  
Revenue of Tonghua Dongbao Pharmaceutical by Product, 2007-2012  
Revenue of Tonghua Dongbao Pharmaceutical by Region, 2007-2012  
Gross Margin of Tonghua Dongbao Pharmaceutical by Product, 2007-2012  
Tonghua Dongbao Pharmaceutical's Revenue from Top 5 Clients and % of Total Revenue, 2009-2012  
Namelist and Revenue Contribution of Tonghua Dongbao Pharmaceutical's Top 5 Clients, 2011-2012  
Revenue and YoY Growth Rate from Insulin Business of Tonghua Dongbao Pharmaceutical, 2007-2012  
Revenue, Net Income and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2010-2015  
Holding Subsidiaries of Wanbang Biopharmaceuticals  
Total Assets and Net Income of Wanbang Biopharmaceuticals, 2009-2011  
Insulin Products of Gan & Lee Pharmaceuticals  
Revenue and Net Income of Gan & Lee Pharmaceuticals, 2008-2010  
Revenue, Net Income and YoY Growth Rate of Nanjing Xinbai Pharmaceutical, 2007-2011  
Revenue from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011  
Gross Profit and Gross Margin from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011

## I would like to order

Product name: China Insulin Industry Report, 2012-2015

Product link: <https://marketpublishers.com/r/CCE9664746CEN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCE9664746CEN.html>